middle.news
Telix Hits US$804M Revenue Mark, Boosted by Gozellix US Launch and Varian Deal
8:02pm on Tuesday 20th of January, 2026 AEDT
•
Healthcare
Read Story
Telix Hits US$804M Revenue Mark, Boosted by Gozellix US Launch and Varian Deal
8:02pm on Tuesday 20th of January, 2026 AEDT
Key Points
FY 2025 revenue of US$804 million meets upgraded guidance
Q4 2025 revenue up 46% year-over-year to US$208 million
Successful US launch of Gozellix drives Precision Medicine growth
Multiple clinical trials progressing globally, including ProstACT and SOLACE
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE